We distribute our research widely to institutional and retail investors through various channels, including our proprietary database, website, and other platforms (such as Bloomberg, Thomson Reuters and Factset).

We are fully MiFID II compliant. Our research is paid for by our corporate clients, and we do not carry out any execution business.

Published reports can be obtained by searching our Research Library below, or directly from the relevant Company Pages.

Advanced search
Date range (dd-mm-yyyy)


Broadened scope for current MCY-M11 Phase I study

Lighthouse | 18 August 2020


Transformational £15m capital raise closes

Update | 12 August 2020

Hutchison China MediTech

Innovative pipeline closer to realising its potential

Update | 10 August 2020


Material fund raise means clinical progress in sight

Lighthouse | 22 July 2020


New products, new deals, attractive prospects

Lighthouse | 15 July 2020

Futura Medical

FDA green lights MED3000 for OTC approval

Update | 14 July 2020


Apeiron licence broadens the MaxCyte opportunity

Lighthouse | 08 July 2020


AXL-erating towards new opportunities

Outlook | 29 June 2020

Futura Medical

AGM statement confirms MED3000 filings on track

Update | 29 June 2020


Swings and roundabouts

Update | 29 June 2020
322 results found.